Print

Antisoma's Stock Falls On Phase III Miss With R1549 
10/19/2005 5:11:05 PM

Antisoma plc's share price was halved Monday after the company announced its lead product, R1549, failed in a Phase III ovarian cancer trial - survival of R1549-treated patients was no better than patients in the comparative arm.
//-->